Tempest Therapeutics Inc 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedJune 30,2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromto.Commission File No.001-35890 Tempest Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerginggrowth company. See the definitions of “large accelerated filer,” accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 ofthe Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒The number of shares of Registrant’s Common Stock, $0.001 par value per share, outstanding as of August 4, 2025 was4,440,161. INDEX TO FORM 10-Q Page Special Note Regarding Forward-Looking Statements3PART I — FINANCIAL INFORMATION5Item 1.Financial Statements (unaudited):5Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 20245Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025and 20246Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June30, 2025 and 20247Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 20248Notes to Condensed Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures28 PART II — OTHER INFORMATION Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds81Item 3.Defaults Upon Senior Securities81Item 4.Mine Safety Disclosures81Item 5.Other Information81Item 6.Exhibits82Signatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements (including within the meaning of Section 21E of theSecurities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”))about us and our industry that involve substantial risks and uncertainties. These statements may discuss goals, intentions andexpectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs ofour management, as well as assumptions made by, and information currently available to, our management. Forward-lookingstatements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, andinclude words such as “may,” “will,” “should,” “would,” “could,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,”“intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-lookingstatements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of futureperformance. Actual results could differ materially from those contained in any forward-looking statement as a result of variousfactors, including, without limitation: whether we are successful in implementing our strategic review (which includes our plans toadvance our clinical-stage programs and maximize stockholder value); our strategies, prospects, plans, expectations or objectivesfor future operations; the progress, scope or timing of the development of our product candidates; the benefits that may be derivedfrom any future products or the commercial or market opportunity with respect to any of our future products; our ability to protectour intellectual property rights; our anticipated operations, financial position, ability to raise capital to fund operations, revenues,costs or expenses;